Sanara MedTech Q4 Earnings Call Highlights

Sanara MedTech (NASDAQ:SMTI) reported fourth-quarter and full-year 2025 results highlighting grounds yearly revenue, improved profitability, and advancement successful its modulation to a “pure-play” surgical institution pursuing the wind-down of its Tissue Health Plus (THP) segment.

President and CEO Seth Yon said the institution exceeded $100 cardinal successful nett gross for the archetypal time, generating $103.1 million successful 2025 nett revenue, up 19% twelvemonth implicit year. Yon emphasized that the institution delivered this maturation portion keeping its tract income squad dependable astatine 40 representatives astatine year-end, citing the show of its hybrid commercialized exemplary that combines nonstop reps with a increasing web of autarkic distributors.

→ Planet Labs: The Satellite Stock That Keeps Shooting to the Moon

Yon besides pointed to improving profitability metrics successful 2025, including an astir 200 ground point betterment successful gross borderline to 93% for the afloat year. The institution reduced its nett nonaccomplishment from continuing operations by $1.5 million, oregon 80%, and improved adjusted EBITDA by $7.9 million, oregon 86%, to $17 million for the year, according to Yon.

Sanara generated $6.8 million successful currency provided by operations successful 2025, a marked alteration from $24,000 of currency utilized successful operations successful 2024. Management attributed the betterment to operating show and moving superior management.

→ Trash to Treasure: 3 Waste Removal Stocks to Minimize Volatility

For the 4th quarter, Sanara posted nett gross of $27.5 million, up 5% twelvemonth implicit year. Yon said maturation was mostly driven by income of brushed insubstantial products, with a humble publication from bony fusion products.

Management noted a examination contented tied to the anterior year: fourth-quarter 2024 results included astir $1.8 million of BIASURGE income related to an manufacture disruption caused by Hurricane Helene. Excluding that impact, Sanara said fourth-quarter 2025 nett gross accrued 13% twelvemonth implicit year. Yon added that gross landed astatine the precocious extremity of the preliminary scope the institution provided successful a January 23, 2026 property merchandise and aligned with expectations discussed connected its third-quarter call.

→ Active ETFs Surge Past Passive, and These Are successful the Lead

Yon outlined advancement crossed 3 commercialized initiatives the institution views arsenic cardinal maturation drivers:

• Strengthening relationships with autarkic distributors: Sanara ended 2025 with over 450 contracted distributors, up from over 350 astatine the extremity of 2024. Yon said the institution has accrued its absorption connected onboarding, training, and associated surgeon acquisition with caller distributor partners.

• Selling into caller healthcare facilities: Sanara said it achieved its people of selling into over 1,450 healthcare facilities by the extremity of 2025, compared with over 1,300 successful 2024. Yon noted that the company’s products were contracted oregon approved for merchantability successful over 4,000 facilities astatine year-end, which absorption described arsenic a runway for further expansion.

• Expanding penetration wrong existing facilities: The institution reported beardown year-over-year maturation successful its surgeon lawsuit basal successful some the 4th fourth and afloat year, with caller surgeon users spanning specialties including spine and orthopedics arsenic good arsenic general, plastic, and vascular surgery. Yon said surgeon penetration successful existing facilities remains “relatively low,” calling deeper penetration 1 of the company’s largest remaining opportunities.